Please assess the completion status of the following clinical trial:

Trial Title: Pegaferon and Ribavirin for Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C~* Age between 15 and 65~Exclusion Criteria:~* previous treatment for chronic hepatitis C~* co-infection with human immunodeficiency virus or hepatitis B virus~* major thalassemia or hemophilia~* active drug user~* being treated for major depression or psychosis~* decompensated cirrhosis~* serum creatinine \> 1.5 mg/dL~* solid organ transplant~* untreated thyroid disease~* uncontrolled diabetes mellitus~* uncontrolled autoimmune disease~* advanced cardiac or pulmonary disease.~* planning to become pregnant in the next 1.5 years~* patients with inadequate contraception~* not consenting to the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).